Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Treace Medical Concepts Q3 2026 Results: Net Loss of $12.6M, Loss Narrows

Treace Medical Concepts, Inc. filed this Form 10-Q for the quarter ended September 30, 2026, reporting 65,559,597 shares of common stock outstanding as of October 30, 2026. The company is focused on managing expenses to offset revenue growth shifts and navigating competition in the bunion surgery market, including its flagship Lapiplasty system.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue48.350.2
Gross profit38.439.7
Net income-12.6-16.3
EPS (diluted, $ a share)$-0.19$-0.26

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-3.9%
Gross margin79.5%
Operating margin-23.9%
Source

10-Q filed with the SEC, NASDAQ: TMCI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Treace Medical Concepts, Inc.: key numbers

Share price
$4.42Close, Nov 16
Market cap
$290M
Shares outstanding
65.56MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Treace Medical Concepts, Inc.

All →
7:05 AM ET 8-K
Financial Results

Treace Medical Concepts Financial Results

Treace Medical Concepts reported Q3 2026 revenue of $48.3 million, a 4% decrease year-over-year primarily due to a shift toward lower-priced minimally invasive products. Despite the revenue dip, the company improved its net loss by 23% to $12.6 million and achieved positive Adjusted EBITDA of $0.3 million through targeted expense reduction initiatives.

Term
Q3 2026

“We are encouraged by our third quarter performance, reflecting accelerated double-digit case volume growth and continued market share gains – driven by increasing adoption of our comprehensive range of best-in-class bunion systems, as well as our expanding portfolio of new technologies including our SuperBite™ compression screws.”

John T. Treace, CEO and Chairman of Treace Medical

“We continue to make disciplined investments in key growth initiatives with an emphasis on our product pipeline, while staying focused on improving profitability and reducing cash usage. We believe this balanced approach positions us to build momentum and deliver stronger growth to finish the year.”

John T. Treace, CEO and Chairman of Treace Medical

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.